Mr. Nasheed is diagnosed with cerebral palsy and is suffering from severe skeletal muscle spasms due to cerebral palsy. The drug, dantrolene, prevents the release of Ca 2+ from sarcoplasmic reticulum is prescribed to him to manage his muscle spasms. Characters in the case: Mr. Nasheed – the cerebral palsy patient. Adequate information: Mr. Nasheed is suffering from cerebral palsy. He complains of severe skeletal muscle spasms brought on by his condition. He is prescribed dantrolene, a drug that can prevent the release of Ca 2+ from the sarcoplasmic reticulum. To determine: The rationale behind using a drug that can prevent the release of Ca 2+ from sarcoplasmic reticulum, in the management of skeletal muscle spasms of a cerebral palsy patient.

Question

Want to see the full answer?

Answer 1

Question

Chapter 10, Problem 4AYKA

Summary Introduction

Case summary:

Mr. Nasheed is diagnosed with cerebral palsy and is suffering from severe skeletal muscle spasms due to cerebral palsy. The drug, dantrolene, prevents the release of Ca²⁺ from sarcoplasmic reticulum is prescribed to him to manage his muscle spasms.

Characters in the case:

Mr. Nasheed – the cerebral palsy patient.

Adequate information:

Mr. Nasheed is suffering from cerebral palsy. He complains of severe skeletal muscle spasms brought on by his condition. He is prescribed dantrolene, a drug that can prevent the release of Ca²⁺ from the sarcoplasmic reticulum.

To determine:

The rationale behind using a drug that can prevent the release of Ca²⁺ from sarcoplasmic reticulum, in the management of skeletal muscle spasms of a cerebral palsy patient.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Students have asked these similar questions

5G JA ATTC 3 3 CTIA A1G5 5 GAAT I I3 3 CTIA AA5 Fig. 5-3: The Eco restriction site (left) would be cleaved at the locations indicated by the arrows. However, a SNP in the position shown in gray (right) would prevent cleavage at this site by EcoRI One of the SNPs in B. rapa is found within the Park14 locus and can be detected by RFLP analysis. The CT polymorphism is found in the intron of the Bra013780 gene found on Chromosome 1. The Park14 allele with the "C" in the SNP has two EcoRI sites and thus is cleaved twice by EcoRI If there is a "T" in that SNP, one of the EcoRI sites is altered, so the Park14 allele with the T in the SNP has only one EcoRI site (Fig. 5-3). Park14 allele with SNP(C) Park14 allele with SNPT) 839 EcoRI 1101 EcoRI 839 EcoRI Fig. 5.4: Schematic restriction maps of the two different Park14 alleles (1316 bp long) of B. rapa. Where on these maps is the CT SNP located? 90 The primers used to amplify the DNA at the Park14 locus (see Fig. 5 and Table 3 of Slankster et…

From your previous experiment, you found that this enhancer activates stripe 2 of eve expression. When you sequence this enhancer you find several binding sites for the gap gene, Giant. To test how Giant interacts with eve, you decide to remove all of the Giant binding sites from the eve enhancer. What results do you expect to see with respect to eve expression?

What experiment could you do to see if the maternal gene, bicoid, is sufficient to form anterior fates?